The Guardian: Japanese flu drug “clearly effective” in treating coronavirus, says China

24 March 2020
214 Views

Medical authorities in China have said a drug used in Japan to treat new strains of influenza appeared to be effective in coronavirus patients, Japanese media said on Wednesday.

Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.

“It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters on Tuesday.

Patients who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive, compared with a median of 11 days for those who were not treated with the drug, public broadcaster NHK said.

In addition, X-rays confirmed improvements in lung condition in about 91% of the patients who were treated with favipiravir, compared to 62% or those without the drug.

Source: The Guardian

You may be interested

Telegraph: When coronavirus ends, Greece is the first spot to visit
GREECE
shares62 views
GREECE
shares62 views

Telegraph: When coronavirus ends, Greece is the first spot to visit

Panos - Apr 09, 2020

Telegraph’s digital traveller writer Oliver Smith says Greece will be his first holiday destination after the coronavirus crisis ends. In…

The Biggest Financial Contributors To The WHO
GREECE
shares54 views
GREECE
shares54 views

The Biggest Financial Contributors To The WHO

Panos - Apr 09, 2020

As the slow initial U.S. response to the COVID-19 pandemic comes under increasing scrutiny, President Trump has denied any responsibility…

Christine Lagarde: The ECB helps firms & families
FINANCE
shares61 views
FINANCE
shares61 views

Christine Lagarde: The ECB helps firms & families

Panos - Apr 09, 2020

“If not all countries are cured, the others will suffer. Solidarity is in fact self-interest” By Christine Lagarde, President of…

Leave a Comment

Your email address will not be published.